USD 9.59
(1.48%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 4.01 USD | 11.08% |
2022 | 3.61 USD | -32.27% |
2021 | 5.33 USD | -37.44% |
2020 | 8.52 USD | -32.97% |
2019 | 12.71 USD | 49.35% |
2018 | 8.51 USD | 19.69% |
2017 | 7.11 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q3 | 1.39 USD | 82.89% |
2024 Q2 | 0.76 USD | -3.8% |
2024 Q1 | 0.79 USD | -63.08% |
2023 Q1 | 0.70 USD | 66.67% |
2023 Q3 | 0.23 USD | -75.79% |
2023 Q2 | 0.95 USD | 35.71% |
2023 Q4 | 2.14 USD | 830.43% |
2023 FY | - USD | 11.08% |
2022 Q1 | 1.37 USD | 71.25% |
2022 FY | - USD | -32.27% |
2022 Q4 | 0.42 USD | -52.81% |
2022 Q3 | 0.89 USD | -3.26% |
2022 Q2 | 0.92 USD | -32.85% |
2021 Q2 | 1.68 USD | 6.33% |
2021 FY | - USD | -37.44% |
2021 Q1 | 1.58 USD | 8.97% |
2021 Q4 | 0.80 USD | -37.01% |
2021 Q3 | 1.27 USD | -24.4% |
2020 Q4 | 1.45 USD | -32.87% |
2020 Q3 | 2.16 USD | 0.93% |
2020 Q2 | 2.14 USD | -23.02% |
2020 Q1 | 2.78 USD | 0.0% |
2020 FY | - USD | -32.97% |
2019 FY | - USD | 49.35% |
2018 FY | - USD | 19.69% |
2017 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
AbbVie Inc. | 2.73 USD | -46.886% |
Bristol-Myers Squibb Company | 3.88 USD | -3.351% |
Bristol-Myers Squibb Company Ce | 3.88 USD | -3.351% |
Johnson & Johnson | 13.88 USD | 71.11% |
Eli Lilly and Company | 5.80 USD | 30.862% |
Merck & Co., Inc. | 0.14 USD | -2764.286% |
Novartis AG | 7.15 USD | 43.916% |
Pfizer Inc. | 0.38 USD | -955.263% |